Total Payments
$2.4M
2024 Payments
$286,832
Companies
47
Transactions
3,215
Medicare Patients
2,810
Medicare Billing
$855,539
Payment Breakdown by Category
Other$1.7M (70.6%)
Travel$373,394 (15.4%)
Consulting$280,634 (11.6%)
Food & Beverage$56,674 (2.3%)
Education$2,273 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 546 | 60.0% |
| Travel and Lodging | $373,394 | 1,029 | 15.4% |
| Consulting Fee | $280,634 | 97 | 11.6% |
| Honoraria | $257,442 | 152 | 10.6% |
| Food and Beverage | $56,674 | 1,341 | 2.3% |
| Education | $2,273 | 50 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $1.1M | 920 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $610,565 | 886 | $0 (2024) |
| Lundbeck LLC | $196,437 | 293 | $0 (2021) |
| Neurocrine Biosciences, Inc. | $133,369 | 141 | $0 (2024) |
| ABBVIE INC. | $110,303 | 264 | $0 (2024) |
| Kyowa Kirin, Inc. | $64,080 | 83 | $0 (2024) |
| Adamas Pharmaceuticals, Inc. | $60,734 | 84 | $0 (2021) |
| Amneal Pharmaceuticals LLC | $48,363 | 53 | $0 (2024) |
| UCB, Inc. | $37,668 | 84 | $0 (2024) |
| MERZ NORTH AMERICA, INC. | $34,035 | 53 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $286,832 | 384 | Teva Pharmaceuticals USA, Inc. ($152,953) |
| 2023 | $366,254 | 486 | Teva Pharmaceuticals USA, Inc. ($173,263) |
| 2022 | $298,008 | 368 | Teva Pharmaceuticals USA, Inc. ($147,103) |
| 2021 | $270,506 | 315 | Teva Pharmaceuticals USA, Inc. ($133,421) |
| 2020 | $187,365 | 233 | Teva Pharmaceuticals USA, Inc. ($109,910) |
| 2019 | $335,372 | 446 | Teva Pharmaceuticals USA, Inc. ($166,458) |
| 2018 | $337,227 | 468 | Teva Pharmaceuticals USA, Inc. ($124,945) |
| 2017 | $341,824 | 515 | ACADIA Pharmaceuticals Inc ($128,786) |
All Payment Transactions
3,215 individual payment records from CMS Open Payments — Page 1 of 129
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $7.07 | General |
| Category: NEUROLOGY | ||||||
| 12/16/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $7.33 | General |
| Category: Neurology | ||||||
| 12/12/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $20.15 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/10/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: NEUROSCIENCE | ||||||
| 12/09/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Neurology | ||||||
| 12/05/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Honoraria | Cash or cash equivalent | $3,115.00 | General |
| Category: NEUROLOGY | ||||||
| 12/05/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Honoraria | Cash or cash equivalent | $2,225.00 | General |
| Category: NEUROLOGY | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Neurology | ||||||
| 12/03/2024 | Kyowa Kirin, Inc. | Nourianz (Drug) | Food and Beverage | In-kind items and services | $20.57 | General |
| Category: Adenosine A2A Receptors | ||||||
| 12/03/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $8.54 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Honoraria | Cash or cash equivalent | $2,225.00 | General |
| Category: NEUROLOGY | ||||||
| 12/02/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/02/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Education | In-kind items and services | $8.35 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/26/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Food and Beverage | In-kind items and services | $26.07 | General |
| Category: NEUROLOGY | ||||||
| 11/26/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Education | In-kind items and services | $8.35 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/21/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/21/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/20/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $6.52 | General |
| Category: Neurology | ||||||
| 11/19/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Education | In-kind items and services | $1.36 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Neurology | ||||||
| 11/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $0.62 | General |
| Category: Neurology | ||||||
| 11/13/2024 | Amneal Pharmaceuticals LLC | ONGENTYS (Drug) | Travel and Lodging | In-kind items and services | $1,194.74 | General |
| Category: NEUROLOGY | ||||||
| 11/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: Rare Disease | ||||||
| 11/11/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Education | In-kind items and services | $3.40 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 765 | 14,684 | $571,301 | $195,820 |
| 2022 | 16 | 835 | 18,694 | $658,313 | $232,715 |
| 2021 | 15 | 608 | 22,513 | $648,808 | $240,645 |
| 2020 | 13 | 602 | 21,776 | $548,411 | $186,359 |
Total Patients
2,810
Total Services
77,667
Medicare Billing
$855,539
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 214 | 373 | $145,464 | $54,108 | 37.2% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2023 | 30 | 11,180 | $128,905 | $44,990 | 34.9% |
| 99483 | Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | Office | 2023 | 90 | 100 | $69,000 | $22,785 | 33.0% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2023 | 17 | 2,284 | $61,965 | $22,488 | 36.3% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2023 | 27 | 62 | $40,035 | $10,467 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 71 | 88 | $25,963 | $9,158 | 35.3% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 98 | 266 | $23,600 | $7,158 | 30.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 37 | 37 | $19,211 | $7,078 | 36.8% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2023 | 34 | 80 | $17,270 | $5,786 | 33.5% |
| 64611 | Injection of chemical for paralysis of salivary glands on both sides of mouth | Office | 2023 | 18 | 39 | $14,079 | $4,367 | 31.0% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 15 | 15 | $5,721 | $1,777 | 31.1% |
| 11105 | Punch biopsy, each additional skin growth | Office | 2023 | 15 | 30 | $5,502 | $1,666 | 30.3% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 16 | 37 | $6,032 | $1,355 | 22.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 17 | 17 | $3,510 | $1,296 | 36.9% |
| G2252 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2023 | 40 | 50 | $3,250 | $1,006 | 31.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 26 | 26 | $1,794 | $333.84 | 18.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 233 | 418 | $147,554 | $63,181 | 42.8% |
| J0588 | Injection, incobotulinumtoxin a, 1 unit | Office | 2022 | 26 | 15,470 | $178,369 | $61,370 | 34.4% |
| 99483 | Assessment of and care planning for impaired thought processing, typically 50 minutes | Office | 2022 | 128 | 137 | $99,025 | $30,760 | 31.1% |
| J0587 | Injection, rimabotulinumtoxinb, 100 units | Office | 2022 | 15 | 1,808 | $49,051 | $17,208 | 35.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 72 | 72 | $36,216 | $13,495 | 37.3% |
| 64616 | Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | Office | 2022 | 22 | 57 | $36,974 | $9,434 | 25.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 109 | 301 | $28,294 | $8,436 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 67 | $17,749 | $7,472 | 42.1% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 34 | 86 | $17,286 | $6,708 | 38.8% |
About Dr. Fahd Amjad, MD
Dr. Fahd Amjad, MD is a Neurology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/29/2008. The National Provider Identifier (NPI) number assigned to this provider is 1477703312.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Fahd Amjad, MD has received a total of $2.4M in payments from pharmaceutical and medical device companies, with $286,832 received in 2024. These payments were reported across 3,215 transactions from 47 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M).
As a Medicare-enrolled provider, Amjad has provided services to 2,810 Medicare beneficiaries, totaling 77,667 services with total Medicare billing of $855,539. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Washington, DC
- Active Since 09/29/2008
- Last Updated 02/24/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1477703312
Products in Payments
- AUSTEDO (Drug) $826,348
- NUPLAZID (Drug) $610,565
- Austedo XR (Drug) $245,059
- NORTHERA (Drug) $187,451
- INGREZZA (Drug) $66,161
- GOCOVRI (Drug) $65,752
- Duopa (Drug) $63,853
- Xeomin (Biological) $42,072
- Ongentys (Drug) $41,641
- DUOPA (Drug) $40,888
- ONGENTYS (Drug) $40,605
- NOURIANZ (Drug) $39,103
- Neupro (Drug) $37,624
- Nourianz (Drug) $24,976
- RYTARY (Drug) $16,403
- XEOMIN (Biological) $9,320
- Xadago (Drug) $5,923
- MYOBLOC (Biological) $4,318
- SD809-HD (Drug) $4,230
- KYNMOBI (Drug) $3,939
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Washington
Dr. Laxman Bahroo, D.o,, D.O,
Neurology — Payments: $3.4M
Neurology $3.4M
Jessica Ailani, Md, MD
Neurology — Payments: $1.3M
Neurology $1.3M
Fernando Pagan
Neurology — Payments: $1.1M
Neurology $1.1M
Dr. Yasar Torres-Yaghi, M.d, M.D
Neurology — Payments: $868,293
Neurology $868,293
Benjamin Osborne
Neurology — Payments: $770,154
Neurology $770,154
Dr. Faria Amjad, Md, MD
Neurology — Payments: $671,517
Neurology $671,517